Effect of Tofacitinib and Iguratimod in Combination with Methotrexate in the Treatment of Active Rheumatoid Arthritis
Objective To study the efficacy and safety of tofacitinib and iguratimod combined with methotrexate in the treatment of active rheumatoid arthritis(RA).Methods A total of 90 patients with active RA admitted to Fuzhou Municipal Hospital from March 2021 to May 2023 were randomly divided into control group,tofacitinib group and iguratimod group,with 30 patients in each group.The control group was treated with methotrexate alone,the tofacitinib group was additionally treated with tofacitinib,and the iguratimod group was additionally treated with iguratimod.The therapeutic effect and safety of the three groups were compared.Results The response rates of ACR20/50/70 in tofacitinib group and iguratimod group were higher than those in control group(P<0.05),but there was no statistical significance between tofacitinib group and iguratimod group(P>0.05).Erythrocyte sedimentation rate and C-reactive protein in tofacitinib group and iguratimod group at the 3rd and 6th month were lower than those in control group,and lower than those before treatment(P<0.05);the morning stiffness time of tofacitinib group and iguratimod group was shorter than that of control group(P<0.05),but there was no significant difference in morning stiffness time between tofacitinib group and iguratimod group(P>0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion Tofacitinib combined with methotrexate and iguratimod combined with methotrexate in the treatment of active RA can effectively relieve clinical symptoms,reduce inflammation and shorten the morning stiffness time,with good therapeutic effect and high safety.
NETL
NSTL
万方数据
